Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25851756 | 0.91 | TP53 (0.50) | TP53MAPTRXFP1NPC1RAB9A | |
| SCHEMBL25855422 | 0.88 | TP53 (0.55) | TP53MAPTRXFP1NPC1RAB9A | |
| SCHEMBL25851802 | 0.87 | ALDH1A1 (0.46) | TP53MAPTRXFP1NPC1RAB9A | |
| SCHEMBL25836944 | 0.81 | TP53 (0.49) | TP53MAPTRXFP1NPC1RAB9A | |
| SCHEMBL25837025 | 0.81 | TP53 (0.51) | TP53MAPTRXFP1NPC1RAB9A | |
| SCHEMBL25835010 | 0.81 | ALDH1A1 (0.48) | TP53MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL25834992 | 0.78 | ALDH1A1 (0.46) | MAPTNPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL25836975 | 0.77 | ALDH1A1 (0.48) | TP53MAPTRXFP1NPC1RAB9A | |
| SCHEMBL26034490 | 0.75 | TP53 (0.58) | TP53MAPTRXFP1NPC1RAB9A | |
| SCHEMBL26036567 | 0.75 | ALDH1A1 (0.47) | TP53MAPTNPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | CPT1B, MUSK, MYLK2 | TP53 4012/4885MAPT 3973/4885RXFP1 3075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.